Tags

Type your tag names separated by a space and hit enter

Effects of fish oil supplements in NIDDM subjects. Controlled study.
Diabetes Care 1990; 13(8):821-9DC

Abstract

The aim of this study was to evaluate the effects of a fish oil preparation (MaxEPA) on hemostatic function and fasting lipid and glucose levels in non-insulin-dependent diabetic (NIDDM) subjects. Eighty NIDDM outpatients aged 55.9 yr (mean SD 11.5 yr) participated in a prospective double-blind placebo-controlled study of MaxEPA capsules (10 g/day) or olive oil (control) treatment over 6 wk. Patients received either MaxEPA or olive oil in addition to preexisting therapy. Metabolic and hemostatic variables were measured before treatment and after 3 and 6 wk. Platelet membrane eicosapentaenoic acid (EPA) content increased in the treatment group (P less than 0.001). MaxEPA supplementation was associated with a significant fall in total triglycerides (P less than 0.001) but did not affect total cholesterol (P = 0.7) compared with control treatment. Fasting plasma glucose increased after 3 wk (P = 0.01) but not after 6 wk (P = 0.17) treatment with MaxEPA. Spontaneous platelet aggregation in whole blood fell in the MaxEPA group (P less than 0.02) after 6 wk, but there were no changes in agonist-induced platelet aggregation, thromboxane generation in platelet-rich plasma, or plasma beta-thromboglobulin and platelet factor IV levels. An increase in clotting factor VII (P = 0.02), without changes in fibrinogen or factor X levels, occurred in the MaxEPA group. Similar reductions in blood pressure were observed in both groups. Dietary supplementation with MaxEPA capsules (10 g/day) in NIDDM subjects is associated with improvement in hypertriglyceridemia but with deleterious effects in factor VII and blood glucose levels. Most indices of platelet function are unaffected by this therapy.

Authors+Show Affiliations

Academic Unit of Diabetes and Endocrinology, University College, Hampstead, London, United Kingdom.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

2209315

Citation

Hendra, T J., et al. "Effects of Fish Oil Supplements in NIDDM Subjects. Controlled Study." Diabetes Care, vol. 13, no. 8, 1990, pp. 821-9.
Hendra TJ, Britton ME, Roper DR, et al. Effects of fish oil supplements in NIDDM subjects. Controlled study. Diabetes Care. 1990;13(8):821-9.
Hendra, T. J., Britton, M. E., Roper, D. R., Wagaine-Twabwe, D., Jeremy, J. Y., Dandona, P., ... Yudkin, J. S. (1990). Effects of fish oil supplements in NIDDM subjects. Controlled study. Diabetes Care, 13(8), pp. 821-9.
Hendra TJ, et al. Effects of Fish Oil Supplements in NIDDM Subjects. Controlled Study. Diabetes Care. 1990;13(8):821-9. PubMed PMID: 2209315.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effects of fish oil supplements in NIDDM subjects. Controlled study. AU - Hendra,T J, AU - Britton,M E, AU - Roper,D R, AU - Wagaine-Twabwe,D, AU - Jeremy,J Y, AU - Dandona,P, AU - Haines,A P, AU - Yudkin,J S, PY - 1990/8/1/pubmed PY - 1990/8/1/medline PY - 1990/8/1/entrez SP - 821 EP - 9 JF - Diabetes care JO - Diabetes Care VL - 13 IS - 8 N2 - The aim of this study was to evaluate the effects of a fish oil preparation (MaxEPA) on hemostatic function and fasting lipid and glucose levels in non-insulin-dependent diabetic (NIDDM) subjects. Eighty NIDDM outpatients aged 55.9 yr (mean SD 11.5 yr) participated in a prospective double-blind placebo-controlled study of MaxEPA capsules (10 g/day) or olive oil (control) treatment over 6 wk. Patients received either MaxEPA or olive oil in addition to preexisting therapy. Metabolic and hemostatic variables were measured before treatment and after 3 and 6 wk. Platelet membrane eicosapentaenoic acid (EPA) content increased in the treatment group (P less than 0.001). MaxEPA supplementation was associated with a significant fall in total triglycerides (P less than 0.001) but did not affect total cholesterol (P = 0.7) compared with control treatment. Fasting plasma glucose increased after 3 wk (P = 0.01) but not after 6 wk (P = 0.17) treatment with MaxEPA. Spontaneous platelet aggregation in whole blood fell in the MaxEPA group (P less than 0.02) after 6 wk, but there were no changes in agonist-induced platelet aggregation, thromboxane generation in platelet-rich plasma, or plasma beta-thromboglobulin and platelet factor IV levels. An increase in clotting factor VII (P = 0.02), without changes in fibrinogen or factor X levels, occurred in the MaxEPA group. Similar reductions in blood pressure were observed in both groups. Dietary supplementation with MaxEPA capsules (10 g/day) in NIDDM subjects is associated with improvement in hypertriglyceridemia but with deleterious effects in factor VII and blood glucose levels. Most indices of platelet function are unaffected by this therapy. SN - 0149-5992 UR - https://www.unboundmedicine.com/medline/citation/2209315/Effects_of_fish_oil_supplements_in_NIDDM_subjects__Controlled_study_ L2 - https://medlineplus.gov/diabetestype2.html DB - PRIME DP - Unbound Medicine ER -